Aldosterone's rapid, nongenomic effects are mediated by striatin: A modulator of Aldosterone's effect on estrogen action

Endocrinology

Volumn 155, Issue 6, 2014, Pages 2233-2243

  Coutinho, Patricia ^a   Vega, Christopher ^a,b   Pojoga, Luminita H ^a   Rivera, Alicia ^b   Prado, Gregory N ^a,b   Yao, Tham M ^a   Adler, Gail ^a   Torres Grajales, Manuel ^a   Maldonado, Enrique R ^a,b   Ramos Rivera, Arelys ^a   Williams, Jonathan S ^a   Williams, Gordon ^a   Romero, Jose R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CALMODULIN BINDING PROTEIN; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; STRIATIN; UNCLASSIFIED DRUG; HORMONE; MEMBRANE PROTEIN; NERVE PROTEIN; PROTEIN BINDING; REACTIVE OXYGEN METABOLITE; STRN PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; GENETIC TRANSFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ELECTRON MICROSCOPY; IMMUNOPRECIPITATION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

ALDOSTERONE; ANIMALS; CALMODULIN-BINDING PROTEINS; ESTROGENS; HORMONES; IMMUNOPRECIPITATION; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; NERVE TISSUE PROTEINS; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84901418612     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1834     Document Type: Article

References (54)

1. Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov. 2004;3: 27-41.
2. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45: 773-779.
3. Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57: 442-451.
4. Lösel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003;4: 46-56.
5. Hayashi H, Kobara M, Abe M, et al. Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res. 2008;31: 363-375.
6. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor β. Proc Natl Acad Sci USA. 2004;101: 17126-17131.
7. Pojoga LH, Coutinho P, Rivera A, et al. Activation of the mineralocorticoid receptor increases striatin levels.Am J Hypertens. 2012; 25(2): 243-249.
8. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005;19: 1951-1959.
9. Kelly MJ, Levin ER. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab. 2001;12: 152-156.
10. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005;23: 1616-1622.
11. Castets F, Bartoli M, Barnier JV, et al. A novel calmodulin-binding protein, belonging to the WD-repeat family, is localized in dendrites of a subset of CNS neurons. J Cell Biol. 1996;134: 1051-1062.
12. Castets F, Rakitina T, Gaillard S, Moqrich A, Mattei MG, Monneron A. Zinedin, SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain. J Biol Chem. 2000;275: 19970-19977.
13. Pojoga LH, Romero JR, Yao TM, et al. Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II. Endocrinology. 2010;151: 1236-1246.
14. D'Alessio A, Al-Lamki RS, Bradley JR, Pober JS. Caveolae participate in tumor necrosis factor receptor 1 signaling and internalization in a human endothelial cell line. Am J Pathol. 2005;166: 1273-1282.
15. Prado GN, Romero JR, Rivera A. Endothelin-1 receptor antagonists regulate cell surface-associated protein disulfide isomerase in sickle cell disease. FASEB J. 2013;27: 4619-4629.
16. Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb. 2005;12: 138-142.
17. 2 in cultured endothelial cells. Arch Biochem Biophys. 1993; 302: 348-355.
18. Ohashi T, Mizutani A, Murakami A, Kojo S, Ishii T, Taketani S. Rapid oxidation of dichlorodihydrofluorescin with heme and hemoproteins: formation of the fluorescein is independent of the generation of reactive oxygen species. FEBS Lett. 2002;511: 21-27.
19. Brown MR, Miller FJ Jr, Li WG, et al. Overexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cells. Circ Res. 1999;85: 524-533.
20. Gomez-Sanchez CE, de Rodriguez AF, Romero DG, et al. Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology. 2006;147: 1343-1348.
21. Ricchiuti V, Lapointe N, Pojoga L, et al. Dietary sodium intake regulates angiotensin II type 1, mineralocorticoid receptor, and associated signaling proteins in heart. J Endocrinol. 2011;211: 47-54.
22. Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147: 5363-5373.
23. Meltser I, Tahera Y, Canlon B. Glucocorticoid receptor and mito gen-activated protein kinase activity after restraint stress and acoustic trauma. J Neurotrauma. 2009;26(10): 1835-1845.
24. Gonzalez R, Ruiz-Leon Y, Gomendio M, Roldan ER. The effect of glucocorticoids on ERK-1/2 phosphorylation during maturation of lamb oocytes and their subsequent fertilization and cleavage ability in vitro. Reprod Toxicol. 29(2): 198-205.
25. Bernelot Moens SJ, Schnitzler GR, Nickerson M, et al. Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation. 2012;126: 1993-2004.
26. Rozansky DJ, Cornwall T, Subramanya AR, et al. Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway. J Clin Invest. 2009;119: 2601-2612.
27. Chen SY, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA. 1999;96: 2514-2519.
28. Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47: 656-664.
29. Ospina JA, Krause DN, Duckles SP. 17β-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke. 2002;33: 600-605.
30. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293: 2449-2452.
31. Fra AM, Williamson E, Simons K, Parton RG. De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc Natl Acad Sci USA. 1995;92: 8655-8659.
32. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;276: 38121-38138.
33. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol. 2008;48: 359-391.
34. Frank PG, Woodman SE, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol. 2003; 23: 1161-1168.
35. Wyckoff MH, Chambliss KL, Mineo C, et al. Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Gβ(i). J Biol Chem. 2001;276: 27071-27076.
36. Moreno CS, Lane WS, Pallas DC. A mammalian homolog of yeast MOB1 is both a member and a putative substrate of striatin familyprotein phosphatase 2A complexes. J Biol Chem. 2001;276: 24253-24260.
37. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000; 141: 3871-3878.
38. Schäfer N, Lohmann C, Winnik S, et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in dietinduced obesity. Eur Heart J. 2013;34(45): 3515-3524.
39. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology. 2008;149: 1009-1014.
40. Pojoga LH, Adamová Z, Kumar A, et al. Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol. 2011;298: H1776-H1788.
41. Li L, Yang G, Ebara S, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 2001;61: 4386-4392.
42. Schlegel A, Wang C, Pestell RG, Lisanti MP. Ligand-independent activation of oestrogen receptor -by caveolin-1. Biochem J. 2001; 359: 203-210.
43. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998;273: 5419-5422.
44. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Gβ subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996;271: 29182-29190.
45. Park H, Go YM, Darji R, et al. Caveolin-1 regulates shear stressdependent activation of extracellular signal-regulated kinase. Am J Physiol Heart Circ Physiol. 2000;278: H1285-H1293.
46. Gaillard S, Bartoli M, Castets F, Monneron A. Striatin, a calmodulin-dependent scaffolding protein, directly binds caveolin-1. FEBS Lett. 2001;508: 49-52.
47. Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, Rafestin-Oblin ME. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem J. 1996;315(pt 2): 421-427.
48. CaprioM, NewfellBG, la Sala A, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res. 2008;102: 1359-1367.
49. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13: 189-197.
50. Cain JP, Tuck ML, Williams GH, Dluhy RG, Rosenoff SH. The regulation of aldosterone secretion in primary aldosteronism. Am J Med. 1972;53: 627-637.
51. Rousseau MF, Gurné O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol. 2002;40: 1596-1601.
52. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345: 1689-1697.
53. Zhang L, Fishman MC, Huang PL. Estrogen mediates the protective effects of pregnancy and chorionic gonadotropin in a mouse model of vascular injury. Arterioscler Thromb Vasc Biol. 1999;19: 2059-2065.
54. Benoist M, Gaillard S, Castets F. The striatin family: a new signaling platform in dendritic spines. J Physiol Paris. 2006;99: 146-153.